Crystals That Could Change Gene Therapy

MIT's selective crystallization speeds AAV vector output, cuts costs, and signals a major shift in scalable gene therapy manufacturing

29 Oct 2025

MIT researchers have reported a selective crystallisation technique that isolates functional adeno-associated virus vectors, offering a possible shift in how gene therapy materials are produced at scale.

The team demonstrated that under controlled conditions, full AAV capsids, which contain therapeutic genomes, crystallised while empty capsids remained in solution. The study covered serotypes 5, 8 and 9. This divergence provides a physical basis for separating usable vectors from material that adds cost without clinical value. One researcher described the technique as “a long awaited lever for scale that could reshape upstream and downstream strategy”.

Developers have struggled for years to improve the ratio of full to empty capsids, a constraint that has limited production volumes and increased manufacturing expenses. Analysts said the MIT findings could become one of the most significant technical advances in vector manufacturing this year.

Companies with late-stage programmes, including Sarepta Therapeutics, continue to depend on reliable vector output, while contract manufacturers such as Genezen face persistent capacity pressures despite investment in new facilities. A faster purification route could shorten development timelines, reduce costs and broaden patient access.

The prospect of more efficient production may also influence dealmaking. Firms with established vector capabilities could pursue acquisitions to secure technical advantages or extend their manufacturing portfolios. A strategist said that “any group with early access to faster vector production gains immediate leverage in partnerships, pricing and market reach”.

Uncertainties remain. The method’s performance beyond the tested serotypes is unproven, and questions over long-term stability of crystallised capsids, regulatory acceptance and consistency across production sites must be resolved before broad deployment.

Still, industry leaders view these hurdles as manageable given the potential gains. If the approach scales reliably, it could support a new phase of growth in gene therapy and bring commercial supply closer to long-term demand.

For now, manufacturers and investors are monitoring the technology as it moves toward commercial readiness, reflecting expectations that selective crystallisation could redefine production norms in genetic medicine.